scholarly journals Effects of Bifidobacterium animalis ssp. lactis 420 on gastrointestinal inflammation induced by a non‐steroidal anti‐inflammatory drug: a randomized, placebo‐controlled, double‐blind clinical trial

2021 ◽  
Author(s):  
Sanna M. Mäkelä ◽  
Sofia D. Forssten ◽  
Marita Kailajärvi ◽  
Ville L. Langén ◽  
Mika Scheinin ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Double Blind ◽  
Inflammatory Drug ◽  
Bifidobacterium Animalis ◽  
Double Blind Clinical Trial ◽  
Gastrointestinal Inflammation ◽  
Anti Inflammatory

General Practitioners' Evaluation of Side-Effects and Efficacy of Oxamethacin as Compared with Indomethacin

1980 ◽  
Vol 8 (2) ◽  
pp. 156-162 ◽  
Author(s):  
J Polderman ◽  
M Colon
Keyword(s):  
Clinical Trial ◽  
Drug Therapy ◽  
Side Effects ◽  
General Practitioners ◽  
Double Blind ◽  
Inflammatory Drug ◽  
Pathological Conditions ◽  
Maximum Duration ◽  
Double Blind Clinical Trial ◽  
Anti Inflammatory

Sixteen general practitioners conducted a multicentre double-blind clinical trial to compare oxamethacin (100 mg t.i.d.) with indomethacin (50 mg t.i.d.) for a maximum duration of 2 weeks. Each drug was administered to 339 patients suffering from various pathological conditions requiring a non steroidal anti-inflammatory drug. When focusing on patients without associated drug therapy, 126/250 patients (50%) presented a good response on inflammation under oxamethacin and 98/236 patients (42%) a good response under indomethacin (p < 10−2); 141/250 patients (56%) presented a good response on pain under oxamethacin and 117/236 (50%) under indomethacin (p<5.10−2). Side effects and complaints were reported by 34/250 patients (14%) under oxamethacin and by 67/236 (28%) under indomethacin (p < 5.10−5). Some patients stopped treatment because of side-effects: 14/250 (6%) under oxamethacin and 32/236 (14%) under indomethacin (p < 2.10−3).

A Controlled Clinical Trial of a New Anti-Inflammatory Drug, Diftalone, in Rheumatoid Arthritis

1974 ◽  
Vol 2 (5) ◽  
pp. 338-346 ◽  
Author(s):  
Valentin Stroescu ◽  
Carmen Georgescu ◽  
Radu Voiosu
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Trial ◽  
Randomized Trial ◽  
Term Treatment ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Inflammatory Drug ◽  
Long Term Treatment ◽  
Anti Inflammatory

In a double-blind, randomized trial on thirty-two patients affected by classical or definite rheumatoid arthritis, we have tried the effectiveness and safety of 500 mg/day oral diftalone versus 75 mg/day oral indomethacin for a period of six to twelve months treatment. Diftalone proved to be an effective and well tolerated anti-inflammatory drug in long-term treatment of rheumatoid arthritis. Its activity and safety is at least comparable to that achieved by the use of indomethacin.

Sign in / Sign up

Export Citation Format

Share Document